MET and cancer: Consequently, the simultaneous targeting of c-MET and PD-L1 with bispecific antibodies has emerged as an effective therapeutic strategy in c-MET/PD-L1 double-positive cancer cells, leading to promising bispecific antibodies (16, 17).